Koji Ichikawa

发表

Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo

H. Hirai, T. Shimomura, Makiko Kobayashi, 2010, Cell cycle.

Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo

H. Hirai, T. Shimomura, Makiko Kobayashi, 2011, Investigational New Drugs.

Critical aspects of [NiFe]hydrogenase ligand composition.

Koji Ichikawa, Takahiro Matsumoto, S. Ogo, 2009, Dalton transactions.

pH-Dependent isotope exchange and hydrogenation catalysed by water-soluble NiRu complexes as functional models for [NiFe]hydrogenases.

S. Fukuzumi, Y. Higuchi, Koji Ichikawa, 2008, Dalton transactions.

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

T. Shimomura, Koji Ichikawa, Shinichi Hasako, 2010, Molecular Cancer Therapeutics.

Concerto catalysis--harmonising [NiFe]hydrogenase and NiRu model catalysts.

Y. Higuchi, Koji Ichikawa, K. Yoon, 2010, Dalton transactions.

A Functional [NiFe]Hydrogenase Mimic That Catalyzes Electron and Hydride Transfer from H2

Koji Ichikawa, Takahiro Matsumoto, Hidetaka Nakai, 2013, Science.

Heterodinuclear Complex Cp*Ru(CO)2Co(CO)4 (Cp* = η5–C5Me5) Induced Selective Dimerization of Terminal Alkynes

Koji Ichikawa, S. Kitagawa, H. Matsuzaka, 1998 .

pH-Dependent isotope exchange and hydrogenation catalysed by water-soluble NiRu complexes as functional models for [NiFe]hydrogenases.

S. Fukuzumi, Koji Ichikawa, Takahiro Matsumoto, 2008, Dalton transactions.

Abstract C177: TAS-117, a highly selective non-ATP competitive inhibitor of AKT demonstrated antitumor activity in combination with chemotherapeutic agents and molecular targeted drugs.

T. Abe, T. Shimomura, Koji Ichikawa, 2013 .